Inhibition of lysosomal flux in carcinogen-induced head and neck cancer

抑制致癌物诱发的头颈癌中的溶酶体通量

• 批准号: 10306375
• 负责人: UMAMAHESWAR DUVVURI
• 金额: $ 36.8万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10306375
• 关键词: 11q13; Adjuvant Therapy; Alcohols; Antimalarials; Antineoplastic Agents; Apoptosis; Biochemical; Biogenesis; Biological Assay; Calcium; Carcinogens; Cell Survival; Cells; Cessation of life; Chimeric Proteins; Chloride Channels; Chlorides; Chromosomal Duplication; Cisplatin; Clinical Trials; Coupled; Cytotoxic Chemotherapy; Cytotoxic agent; Data; Development; Disease; Drug resistance; Epithelial; Excision; Excretory function; Exocytosis; Exposure to; FDA approved; Genes; Genetic; Head and Neck Cancer; Head and Neck Neoplasms; Head and Neck Squamous Cell Carcinoma; Human; Imaging Techniques; Immune; Ion Channel; Knock-out; Libraries; Link; Lysosomes; MAP Kinase Gene; MAPK Signaling Pathway Pathway; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Measures; Mediating; Membrane Fusion; Methods; Modeling; Molecular; Mus; National Institute of Dental and Craniofacial Research; Oncogenic; Operative Surgical Procedures; Oral cavity; Outcome; Pathology; Pathway interactions; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Pharmacology; Play; Process; Prognosis; Proteomics; Protocols documentation; Radiation; Reporting; Resistance; Role; Sampling; Signal Transduction; TFE3 gene; Testing; Therapeutic; Therapeutic Intervention; Tissues; Tobacco; Toxin; Translating; Up-Regulation; base; cancer cell; cancer drug resistance; cancer therapy; cancer type; cell type; chemoradiation; chemotherapy; clinical investigation; confocal imaging; driving force; effective therapy; experimental study; genetic analysis; genetic manipulation; genomic data; human model; human tissue; improved; improved outcome; inhibitor; knock-down; mortality; mouse model; mutant; neoplastic cell; new therapeutic target; novel; novel drug combination; novel strategies; overexpression; patient derived xenograft model; prevent; public health relevance; synaptotagmin VII; synergism; targeted agent; tool; trafficking; transcription factor; treatment strategy; tumor; tumor growth; tumor xenograft; tumorigenesis

Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that has a dismal prognosis, despite aggressive surgical and adjuvant therapy. The average estimated overall survival for patients is approximately 50% at 5 years (NIDCR.GOV). The high mortality rate demonstrates that current therapeutic strategies are not adequate. In an effort to improve the outcomes for these patients, genetic analysis of SCCHN has been used to identify potential novel therapeutic targets. One of the most commonly altered genes in this malignancy is the calcium activated chloride channel TMEM16A/ANO1. TMEM16A is amplified in 30% of SCCHN, and overexpression is correlated with poor oncologic outcomes in several cancer types. Our recent data demonstrates that TMEM16A expression abrogates cisplatin-induced apoptosis. It is therefore likely that TMEM16A plays a cytoprotective role in cancer cells. How TMEM16A improves the survival and resistance of cancer cells to therapeutic interventions is unknown. Sequestration of the cancer drugs and other toxins by the lysosomes followed by their expulsion through the process of lysosomal exocytosis has emerged as a mechanism that enhances drug resistance of cancer cells. We find that TMEM16A expression is associated with increased lysosomal acidification, biogenesis and exocytosis. We propose that TMEM16A over-expressing cells are more efficient in the expulsion of cytotoxic drugs than wild-type cells. We also postulate that TMEM16A overexpressing tumors are more likely to upregulate lysosomal flux, and therefore contribute to oncogenesis and resistance to cytotoxic chemotherapy. This is a groundbreaking concept, since it identifies a new function of a novel ion channel and a new paradigm in cancer pathology and suggests a new approach to cancer treatment. During this project, we will identify the mechanism of the TMEM16A-dependent cytoprotective upregulation of the lysosomal throughput and sequestration/expulsion of cytotoxic drugs. We will test this hypothesis using human tissues and patient-derived xenograft models. Finally we will test our concepts using the mouse model of human head and neck tumors and the new approaches specifically aimed at suppressing lysosomal biogenesis and exocytosis using repurposed antimalarial drugs. The results for these studies can be directly translated to clinical investigations, by combining anti-lysosomal drugs with conventional cytotoxic agents, noth of which are FDA-approved agents.

头颈部鳞状细胞癌（SCCHN）是一种预后不良的毁灭性疾病， 尽管进行了积极的手术和辅助治疗。患者的平均估计总生存期为 5年时约为50%（NIDCR.GOV）。高死亡率表明，目前的治疗 战略是不够的。为了改善这些患者的预后，SCCHN的遗传分析 已被用于识别潜在的新的治疗靶点。其中最常见的改变基因之一， 在恶性肿瘤中，钙激活的氯离子通道TMEM 16 A/ANO 1。TMEM 16 A在30%的 SCCHN，并且过表达与几种癌症类型中的不良肿瘤学结果相关。我们最近 数据表明TMEM 16 A表达消除了顺铂诱导的细胞凋亡。因此， TMEM 16 A在癌细胞中起细胞保护作用。 TMEM 16 A如何提高癌细胞的存活率和对治疗干预的抗性尚不清楚。 通过溶酶体隔离抗癌药物和其他毒素，然后通过 溶酶体胞吐过程已经成为增强癌细胞耐药性的机制。 我们发现TMEM 16 A表达与溶酶体酸化、生物合成和细胞凋亡有关。 胞吐作用我们认为TMEM 16 A过表达的细胞在排出细胞毒性T细胞中更有效。 药物比野生型细胞。我们还假设TMEM 16 A过表达的肿瘤更可能上调TMEM 16 A的表达。 溶酶体流动，因此有助于肿瘤发生和对细胞毒性化疗的抗性。这是一 开创性的概念，因为它确定了一种新的离子通道的新功能和癌症的新模式 并提出了一种新的癌症治疗方法。 在这个项目中，我们将确定TMEM 16 A依赖的细胞保护上调的机制， 的溶酶体吞吐量和螯合/排出的细胞毒性药物。我们将测试这个假设， 人组织和患者来源的异种移植物模型。最后，我们将使用鼠标模型测试我们的概念 以及专门针对抑制溶酶体的新方法 使用重新利用的抗疟药物的生物发生和胞吐作用。这些研究的结果可以直接 将抗溶酶体药物与常规细胞毒性药物结合应用于临床研究， 其中包括FDA批准的药物。